inclusion criteria: * subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures. * understands and agrees to comply with planned study procedures. * male or non-pregnant female adult ≥60 and ≤ 80years of age or male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity \[body mass index \>30\], cardiovascular disease). * has a laboratory-confirmed sars-cov-2 infection as determined by fda-approved rapid diagnostic (e.g., polymerase chain reaction \[pcr\]) assay within the preceding 7 days (168 hours). * has at least 2 covid-19 related symptoms on the 14-question covid-19 questionnaire. * has peripheral capillary oxygen saturation (spo2) \>93% by pulse oximetry. * c-reactive protein (crp) \>50 mg/l or lymphopenia (\<1.5×109/l) or neutrophilia (\>7.5×109/l). * agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol. * willing to receive 4 injections at separate sites on the thigh or abdomen. * women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through day 29 following randomization. * agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through day 29 following randomization

inclusion criteria: * subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures. * understands and agrees to comply with planned study procedures. * male or non-pregnant female adult ≥60 and ≤ 80years of age or male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity \[body mass index \>30\], cardiovascular disease). * has a laboratory-confirmed sars-cov-2 infection as determined by fda-approved rapid diagnostic (e.g., polymerase chain reaction \[pcr\]) assay within the preceding 7 days (168 hours). * has at least 2 covid-19 related symptoms on the 14-question covid-19 questionnaire. * has peripheral capillary oxygen saturation (spo2) \>93% by pulse oximetry. * c-reactive protein (crp) \>50 mg/l or lymphopenia (\<1.5×109/l) or neutrophilia (\>7.5×109/l). * agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol. * willing to receive 4 injections at separate sites on the thigh or abdomen. * women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through day 29 following randomization. * agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through day 29 following randomization

inclusion criteria: - subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures. - understands and agrees to comply with planned study procedures. - male or non-pregnant female adult ≥60 and ≤ 80years of age or male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity [body mass index >30], cardiovascular disease). - has a laboratory-confirmed sars-cov-2 infection as determined by fda-approved rapid diagnostic (e.g., polymerase chain reaction [pcr]) assay within the preceding 7 days (168 hours). - has at least 2 covid-19 related symptoms on the 14-question covid-19 questionnaire. - has peripheral capillary oxygen saturation (spo2) >93% by pulse oximetry. - c-reactive protein (crp) >50 mg/l or lymphopenia (<1.5×109/l) or neutrophilia (>7.5×109/l). - agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol. - willing to receive 4 injections at separate sites on the thigh or abdomen. - women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through day 29 following randomization. - agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through day 29 following randomization

inclusion criteria: - subject (or their legally authorized representative) is willing and able to provide written informed consent prior to performing study procedures. - understands and agrees to comply with planned study procedures. - male or non-pregnant female adult ≥60 and ≤ 80years of age or male or non-pregnant female adult ≥40 and ≤80 years, with one or more of the following risk factors (asthma, diabetes, hypertension, obesity [body mass index >30], cardiovascular disease). - has a laboratory-confirmed sars-cov-2 infection as determined by fda-approved rapid diagnostic (e.g., polymerase chain reaction [pcr]) assay within the preceding 7 days (168 hours). - has at least 2 covid-19 related symptoms on the 14-question covid-19 questionnaire. - has peripheral capillary oxygen saturation (spo2) >93% by pulse oximetry. - c-reactive protein (crp) >50 mg/l or lymphopenia (<1.5×109/l) or neutrophilia (>7.5×109/l). - agrees to the collection of blood and urine samples, nasal swabs , and non-invasive oxygen monitoring (via pulse oximeter) per protocol. - willing to receive 4 injections at separate sites on the thigh or abdomen. - women of childbearing potential must agree to either abstinence or use of at least one primary form of contraception (not including hormonal contraception) from the time of screening through day 29 following randomization. - agrees to not participate in any other clinical trial (both pharmacologic and other types of interventions) through day 29 following randomization